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ABSTRACT: Peptide nanomaterials have received a great deal of interest in drug-delivery applications due to their
biodegradability, biocompatibility, suitability for large-scale synthesis, high drug-loading capacities, targeting ability, and ordered
structural organization. The covalent conjugation of drugs to peptide backbones results in prolonged circulation time and
improved stability of drugs. Therapeutic efficacy of gemcitabine, which is used for breast cancer treatment, is severely
compromised due to its rapid plasma degradation. Its hydrophilic nature poses a challenge for both its efficient encapsulation into
nanocarrier systems and its sustained release property. Here, we designed a new peptide prodrug molecule for the anticancer
drug gemcitabine, which was covalently conjugated to the C-terminal of 9-fluorenylmethoxy carbonyl (Fmoc)-protected glycine.
The prodrug was further integrated into peptide nanocarrier system through noncovalent interactions. A pair of oppositely
charged amyloid-inspired peptides (Fmoc−AIPs) were exploited as components of the drug-carrier system and self-assembled
into one-dimensional nanofibers at physiological conditions. The gemcitabine integrated nanoprodrug carrier system exhibited
slow release and reduced the cellular viability of 4T1 breast cancer cell line in a time- and concentration-dependent manner.
■ INTRODUCTION
A wide variety of nanostructured drug carriers have been
developed to enhance therapeutic efficacy, increase chemical
and biological stability, reduce systemic toxicity, provide
controllable drug delivery, and overcome both underdosing
and overdosing issues.1 The nanocarriers are composed of
organic materials including polymers, liposomes, vesicles,
peptides, and inorganic materials such as gold nanoparticles
and quantum dots to serve as a possible drug vehicle for cancer
treatment.2 Among them, self-assembled peptide systems hold
great importance for drug delivery in terms of their
biodegradable and biocompatible properties, suitability for
large-scale synthesis, high drug-loading capacities, stimuli
responsiveness, and ordered structural organization achieved
by noncovalent interactions such as van der Waals, electrostatic,
hydrogen bonding, and π−π stacking.3−5 A pair of main
strategies are involved in drug delivery approaches: (i) physical
encapsulation of drug into the delivery vehicles and (ii)
covalent modification of drug with different moieties, called a
prodrug strategy.6,7 In the former strategy, various peptidic
structures were utilized to load either hydrophobic or
hydrophilic anticancer drugs that allowed the sustained release
of drug together with poor ability for membrane penetration.8,9
In addition, self-assembled peptide amphiphile (PA) nanofibers
encapsulating a hydrophobic drug, camptothecin, were shown
to have great therapeutic potential through passive tumor
targeting for both in vitro and in vivo studies.10 However, the
latter one offers prolonged circulation times and prevents
degradation or conversion of drug to its inactive metabo-
lites.11,12 For instance, the conjugation of peptides to anticancer
drug paclitaxel (PTX) resulted in the prevention of tumor
growth in prostate cancer compared to PTX alone due to
increased plasma and microsomal half-life.13 In another study,
PTX was anchored to the cleavable Gly−Phe−Leu−Gly
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(GFLG) sequence, which allowed its encapsulation into folate
receptor (FR)-targeted liposomes to reduce systemic toxicity
and lead to increased drug loading for breast cancer
treatment.14
Gemcitabine, a cytotoxic nucleoside analog, has a unique
mode of action that causes DNA chain termination and inhibits
DNA synthesis, which further inhibits cell division.15 This
mode of action results in a broad spectrum of activity in many
type of solid tumors.16 In addition, gemcitabine, which is
Federal Drug Administration approved and clinically used as a
chemotherapeutic for the treatment of patients with metastatic
breast cancer, provides response rates ranging from 14 to 37%
as a first-line therapy and 23−42% as a salvage therapy.16−18
Furthermore, side effects such as nausea, vomiting, and flu-like
symptoms occurred less commonly in breast cancer patients
treated with gemcitabine, showing good tolerability of this
chemotherapeutic.16,19 However, due to the hydrophilic nature
of gemcitabine, its activity has been limited by several factors,
such as short plasma half-life and poor uptake by cells, because
of its inability to cross lipid-rich cell membranes.20,21 To
overcome these drawbacks, several strategies have been
developed for effective delivery of gemcitabine, and most of
them are based on the chemical modification of 4-amino group
of gemcitabine to eliminate its rapid metabolism driven by
cytidine deaminase present in bodily fluids.22 Based on these
strategies, gemcitabine was conjugated to different moieties
such as cleavable linkers,23 polymers,24 and amphiphilic hybrid
systems25 to prevent deamination and, hence, to provide
improved drug release behavior, longer circulation time, and
enhanced therapeutic efficacy against several cancer cell lines.
The peptide segment composed of diphenylalanine (FF)
residues, which are known to self-assemble into well-ordered
structures and play a decisive role in fibril formations due to the
interactions between FF aromatic moieties, was systematically
studied by several groups, and this ultrashort sequence was
further modified by the introduction of 9-fluorenylmethoxy
carbonyl (Fmoc) group to strengthen aromatic stacking and the
overall self-assembly process.26,27 Thus, a molecular model of
Fmoc−FF system is more advantageous for controlled drug-
release applications. In this study, we designed Fmoc-
conjugated oppositely charged amyloid inspired peptides,28,29
Fmoc−AIP1 (Fmoc−EFFAAE−Am) and Fmoc−AIP2
(Fmoc−KFFAAK−Am), to serve as a possible drug-delivery
vehicle by taking advantage of hydrophobic and π−π stacking
Scheme 1. Synthesis of Fmoc−G−Gem Derivative
Figure 1. (A) Chemical representations of Fmoc−G−Gem, Fmoc−AIP1 (Fmoc−EFFAAE) and Fmoc−AIP2 (Fmoc−KFFAAK). (B) Schematic
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interactions derived from phenylalanine residues and fluorenyl
moieties as well as electrostatic interactions due to the charged
residues. Furthermore, gemcitabine was conjugated to Fmoc−
glycine molecules (Fmoc−G−Gem) through amide formation
not only to block the 4-amino group of the drug but also to add
hydrophobicity and facilitate its integration into the system
composed of Fmoc−AIPs. In addition to this smart design
strategy, we aimed to combine two main drug-delivery
approaches into one system by using both noncovalent
integration and prodrug strategies to overcome drawbacks of
the drug.
■ RESULTS AND DISCUSSION
Gemcitabine-mediated breast cancer therapy faces several
obstacles, such as high hydrophilicity and rapid plasma
metabolism upon its enzymatic conversion in the blood, liver,
and tumor tissue.20 We hypothesized that protection of amino
group of gemcitabine would prevent these drawbacks and
improve the stability and cytotoxic activity of gemcitabine when
formed into a prodrug and incorporated into a peptide-based
carrier system. For this purpose, the 4-N position of
gemcitabine was protected by conjugating it to the C-terminal
of Fmoc−glycine molecules to afford Fmoc−G−Gem (Scheme
1 and Figures S1 and S2). For the delivery of prodrug, amyloid-
inspired Fmoc−AIP1 and Fmoc−AIP2 were used as the two-
component-carrier system (Figure 1A). The addition of Fmoc
groups enhances the hydrophobicity of the system and the self-
assembly of fiber formation governed by hydrophobic
interactions.30
The peptides were synthesized by using solid-phase peptide
synthesis strategy, and their chemical structures were verified by
liquid chromatography and mass spectrometry (Figure S3).
The hydrophobic nature of Fmoc−G−Gem enables the
stacking of aromatically rich oppositely charged Fmoc−AIPs
(Figure 1B). It is clear from the scanning transmission electron
microscope (STEM) images that while the co-assembled
system of Fmoc−AIPs showed a high-aspect-ratio nanofiber
formation (Figure S4A), only Fmoc−G−Gem did not exhibit
any structural organization (Figure S4B). Besides hydrophobic
and π−π interactions among Fmoc groups and phenylalanine
residues, electrostatic interactions between the hydrophilic Lys
and Glu moieties led to the formation of one-dimensional self-
assembled nanofibers (Figure 1C).
In aqueous solution, while individual molecules (Fmoc−
AIP1, Fmoc−AIP2, and Fmoc−G−Gem) have a critical
aggregation concentration of ca. 50 μM (Figure S5A),
Fmoc−AIPs (the critical aggregation concentration is ca. 5
μM) self-assemble into peptide nanofibers composed of a
hydrophilic outer shell exposed to the aqueous phase and a
hydrophobic inner core interacting with Fmoc−G−Gem
molecules, suggesting that π−π interactions and packing effects
between both Fmoc units and phenylalanine residues reinforce
the self-assembly of these hydrophobic units (Figure S5B).
Based on the concentrations determined by Nile red assay,
which is a fluorescent solvatochromic probe, to determine
critical aggregation concentration of supramolecular systems,
the secondary structures of Fmoc−AIPs and Fmoc−AIPs with
Fmoc−G−Gem were assessed using circular dichroism (CD)
and Congo Red (CR) and Fourier transform−infrared (FT−
IR) analysis.
The CD spectra displayed negative bands at 225 and 221 nm
for Fmoc−AIPs and Fmoc−AIPs with Fmoc−G−Gem (Figure
2A), respectively, which showed a red shift relative to typical β-
sheet spectrum with a minimum at 216 nm due to twisted
structure,31,32 while Fmoc−AIP1 or Fmoc−AIP2 alone
preserved their random coil structure (Figure S6) at
physiological conditions. Amyloid fibril detection was quanti-
tatively assessed by CR assay, which lies parallel to the fibril axis
and induced a red shift in the absorption maximum from 484 to
500 and 520 nm for Fmoc−AIPs and Fmoc−AIPs with Fmoc−
G−Gem, respectively, as a result of interaction with β-sheet rich
amyloid fibrils (Figure 2B).33 The β- sheet arrangements of
Fmoc−AIPs are in agreement with FT−IR analysis. The FT−
IR spectra of self-assembled Fmoc−AIPs and Fmoc−AIPs with
Fmoc−G−Gem showed an amide I band between 1620 and
1640 cm−1 associated with CO stretching, while the peak
that appeared in the amide II band at 1546 cm−1 was attributed
to N−H bending, which suggests the availability of
intermolecular hydrogen-bonded structure in the system.31
The Fmoc−G−Gem characteristic peak for C−F stretching
appeared at 1079 cm−1, and its integration within self-
assembled Fmoc−AIPs resulted in a red shift to 1031 cm−1,
while Fmoc−AIPs did not show any similar peaks in that region
(Figure 2C).34 X-ray diffraction patterns of Fmoc−AIPs and
Fmoc−AIPs with Fmoc−G−Gem supported the results
acquired from FT−IR spectroscopy, which showed evidence
of the β-sheets (broad peak at 2θ = 19.06°, d spacing of 4.8 Å)
observed in both groups (Figure S7).35
After the confirmation of the integration of prodrug molecule
into amyloid-inspired nanofibers, prodrug release studies were
Figure 2. Secondary structure analysis of Fmoc−AIPs, Fmoc−G−
Gem, and Fmoc−AIPs with Fmoc−G−Gem conducted by (A)
circular dichroism. (B) Congo Red assay at physiological conditions.
(C) FT−IR analysis using the dried samples.
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carried out at acidic environment to mimic extracellular matrix
of tumor tissue.36 Major factor that limits the encapsulation of
pharmaceuticals to peptide-based nanocarriers is their inability
to be entrapped within the system due to lack of interactions
between drug and peptide.37 Therefore, in our system, the
Fmoc moiety of Gem enables the avoidance of the hydrophilic
nature of Gem and enhances the noncovalent interactions. The
fibrillar network of Fmoc−AIPs encapsulated hydrophobic
Fmoc−G−Gem and released it in a controlled manner. As
shown in Figure 3, Fmoc−AIPs have a stable release profile.
The release of Fmoc−G−Gem from Fmoc−AIPs exhibited a
biphasic pattern that was characterized by a fast initial release
during the first 15 h, followed by a slower controlled release. As
a cumulative release of the third week, even in acidic
conditions, 37% of Fmoc−G−Gem was released.
Dose-dependent cytotoxicity evaluation of Fmoc−AIPs by
using 4T1 breast cancer cell line revealed that the Fmoc−AIPs
carrier system is biocompatible at concentrations below 125
μM after both 24 and 48 h (Figure S8). Fmoc−G−Gem and
Gem-only groups were also examined by Alamar blue assay, and
their IC50 values were calculated as 12.23 ± 1.44 and 11.67 ±
1.46 μM for 24 h and 1.25 ± 1.14 and 6.77 ± 2.11 μM for 48 h,
respectively.
Because the doubling time of 4T1 cells is 25 h38 and
gemcitabine disrupts DNA strand elongation during DNA
replication,39 the more-pronounced cytotoxic effect of both
Fmoc−G−Gem and Gem-only treatments was observed at 48
h compared to the results from 24 h. The biodegradability of
peptide assemblies and supramolecular architectures via
different proteases has been studied in different studies.40,41
Under the nonspecific enzymatic activity of proteases, peptide
assemblies can be easily degraded into the building blocks at
physiological conditions.42,43 It is also possible to integrate
sequence specific cleavable domains to control the biodegrad-
ability of peptide assemblies under specific protease activity.44,45
In our approach, the 4-N position of gemcitabine was
chemically conjugated to the C-terminal of Fmoc−glycine
molecules through amide bond formation, and the nonspecific
proteolytic degradation of the nanocarrier system could
facilitate release of the drug molecules under cellular metabolic
activity. The promoted cytotoxic effect determined via cellular
viability experiments also pointed us toward the enhanced
bioavailability and proper release of the active molecules from
the carrier system. The cytotoxic effect of integrated Fmoc−G−
Gem was also investigated for 24 and 48 h (Figure S9) and
supported the drug-release behavior discussed above. During
the first 24 h, 15% of Fmoc−G−Gem was released through the
Figure 3. Release behavior of Fmoc−G−Gem through Fmoc−AIPs
for 480 h (20 days) at pH 5.5.
Figure 4. Representative images of live (green) and dead (red) assay of 4T1 cells treated with Fmoc−AIPs, Gem only, Fmoc−G−Gem, and Fmoc−
AIPs with Fmoc−G−Gem during 4 days with a 1 day interval.
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Fmoc−AIP nanocarrier system at pH 5.5, and the IC50 value for
integrated Fmoc−G−Gem was 23.98 ± 4.46 μM for 24 h
(Figure S9), meaning that the concentration of integrated
Fmoc−G−Gem should be within this range to reach the IC50 of
free Fmoc−G−Gem, which is 12.23 ± 1.44 μM at 24 h.
The live−dead assay was performed to demonstrate the
effect of both Fmoc−G−Gem and Fmoc−AIPs with Fmoc−
G−Gem at a 1 day interval during 4 days of incubation (Figure
4). Although a significant difference was not observed between
the viability of the cells treated with Fmoc−AIPs with Fmoc−
G−Gem during 72 h, strikingly, the Fmoc−G−Gem-integrated
Fmoc−AIP system showed a more-cytotoxic effect on 4T1 cells
after 96 h of culture than that of individual Fmoc−G−Gem and
Gem-only groups at the end of fourth day due to the sustained
release behavior (Figure 5).
■ CONCLUSIONS
In conclusion, we have designed and characterized a new
nanocarrier drug-delivery system that combined two drug-
delivery strategies to develop an effective prodrug−carrier
system. The conjugation of gemcitabine to Fmoc−glycine was
followed by the noncovalent integration of Fmoc−G−Gem
into Fmoc−AIPs, which self-assembled into one-dimensional
nanofibers. The prodrug dosage can be adjusted without
disrupting the self-assembly process, and supramolecular
architecture formed by the binary self-assembled amyloid-
inspired peptide nanofiber system enables the release of the
drug in a controlled fashion and provides stability due to the
preservation of the 4-N position of the drug. The gemcitabine-
integrated nanoprodrug carrier system showed significant
reduction in cell viability of the breast cancer cell line without
inducing any of the toxicity associated with Fmoc−AIPs. The
strategy demonstrated in this work not only provides a
promising approach as an alternative therapy for breast cancer
treatment but could also be explored for the delivery of other
hydrophilic drugs. It provides new opportunities for highly
therapeutic drugs with modest clinical benefit due to delivery




acids, [4-[α-(2′,4′-dimethoxyphenyl) Fmoc aminomethyl]
phenoxy] acetamidonorleucyl-MBHA resin (Rink amide
MBHA resin), Wang resin, 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU), and O-
(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoro-
borate (TBTU) were purchased from NovaBiochem. Gemci-
tabine was purchased from Carbosynth. Lauric acid and N,N-
diisopropylethylamine (DIEA) were purchased from Merck.
Other chemicals were purchased from Alfa Aesar or Sigma-
Aldrich and used without any purification. Deionized water
(resistance of 18 MΩ.cm) was used during the experiments.
Synthesis of Gemcitabine Conjugated Amino Acid,
Fmoc−G−Gem. The compound was synthesized based on a
previously published procedure with slight modifications.
Fmoc−Gly−OH (149 mg, 0.5 mmol) dissolved in anhydrous
DMF (3−4 mL) was cooled to 0 °C. TBTU (215 mg, 0.66
mmol) and DIEA (165 μL, 1.08 mmol) were added individually
into the solution and stirred for 30 min. Then, gemcitabine
(165 mg, 0.58 mmol) was added and stirred for another 30 min
at 0 °C. The reaction mixture was left at room temperature and
stirred for 18 h. The compound was concentrated in a rotary
evaporator and purified with column chromatography (1:9
MeOH/DCM, Rf = 0.3, crude yield: 61%). 1H NMR (400
MHz, DMSO-d6, δ): 8.27 (d, J = 7.6 Hz, 1H), 7.90 (d, J = 7.5
Hz, 2H), 7.73 (d, J = 7.4 Hz, 2H), 7.65 (t, J = 6.0 Hz, 1H), 7.43
(t, J = 7.4 Hz, 2H), 7.34 (t, J = 7.4 Hz, 2H), 7.23 (d, J = 7.7 Hz,
1H), 6.34 (d, J = 6.4 Hz, 1H), 6.19 (m, 1H), 5.31 (brs, 1H),
4.32 (m, 2H), 4.25−4.20 (m, 2H), 3.90 (m, 2H), 3.82 (m, 1H),
3.62 (m, 2H), 3.15 (m, 1H). 13C NMR (100 MHz, DMSO-d6,
δ): 171.25, 163.14, 157.03, 154.59, 145.43, 144.27, 141.20,
128.11, 127.55, 125.68, 120.58, 96.32, 81.49, 66.25, 55.27,
54.04, 47.08, 44.91, 42.28. Electrospray ionization time-of-flight
Figure 5. Rate of cellular viability for 24, 48, 72, and 96 h. Fmoc−AIPs (black), Fmoc−AIPs with Fmoc−G−Gem (blue), Fmoc−G−Gem (green),
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high-resolution mass spectrometry (m/z): [M + H]+ calcd for
C26H24F2N4O2, 543.1613; found, 543.1702; [M + Na]
+:
565.1518.
Synthesis and Characterization of Fmoc−AIPs. Fmoc-
protected amyloid-inspired peptides were synthesized by using
a solid-phase peptide synthesis method. Fmoc−AIP1 and
Fmoc−AIP2 peptides were prepared on a 0.5 mmol scale by
repeated amino acid couplings using Fmoc-protected amino
acid (2 equiv), HBTU (1.95 equiv), and DIEA (3 equiv).
MBHA Rink amide resin was used as solid support to construct
the peptides. A Fmoc-protecting group of amino acids, except
that of the final residue, was removed through treatment with
20% piperidine−DMF solution for 20 min. Cleavage of the
peptides from resin and deprotection of acid-labile-protected
amino acids were carried out with a mixture of TFA, TIS, and
H2O at a ratio of 95:2.5:2.5 for 2.5 h. Excess TFA and organic
solvents were removed by rotary evaporation under reduced
pressure, and the remaining peptide was precipitated using
diethyl ether at −20 °C overnight. The centrifuged white
peptide precipitate was dissolved in water and freeze-dried for 3
days. Positively charged Fmoc−AIP2 was treated with 1 mM
HCl and freeze-dried again to remove residual TFA. The
peptides were identified and analyzed by reverse-phase high-
performance liquid chromatography monitored at 220 nm on
an Agilent 6530 accurate-mass quadrupole time-of-flight mass
spectrometry device equipped with an Agilent 1200 high-
performance liquid chromatograph. While an Agilent Zorbax
Extend-C18 (50 × 2.1 mm) column with a mobile phase of a
water and acetonitrile mixture (0.1% NH4OH) was used during
the identification of negatively charged Fmoc−AIP1, a
Phenomenex Luna 3 μ C8 100A (50 × 3.00 mm) column as
the stationary phase and a water−acetonitrile gradient with a
0.1% volume of formic acid as the mobile phase were used to
elucidate the positively charged Fmoc−AIP2.
Preparation of Fmoc−G−Gem Integrated Fmoc−AIPs
Carrier System. Fmoc−AIP1 and Fmoc−AIP2 solutions at a
0.005% (w/v) concentration were prepared at pH 7.4 in water.
The stock solution of Fmoc−G−Gem (18.5 mM) was
dissolved in DMSO. The stock drug solution was first mixed
with positively charged Fmoc−AIP2, and then co-assembly was
triggered upon addition of the negatively charged Fmoc−AIP1
at physiological conditions at a 1:1 volumetric ratio. The final
Fmoc−G−Gem concentration within Fmoc−AIPs was ad-
justed to 60 μM, and the final DMSO concentration in the
system was 1% (w/v).
Critical Aggregation Concentration Determination.
To determine the transition phase between peptide assemblies
and to control the morphologies, hydrophobic Nile red (9-
diethylamino-5-benzo[α]phenoxazinone) fluorescent probe
assay was applied to the peptide solutions (ranging from 1
mM to 0.244 μM) prepared in distilled water at around pH 7. A
1.25 mM stock solution of Nile red was prepared in ethanol (1
mL) and then diluted to 78.12 μM by using ethanol. The
peptide solutions prepared at different concentrations were
mixed with the same amount of the dye solution and incubated
overnight at room temperature. The final Nile red concen-
tration in the mixtures was 250 nM, and 0.31% (v/v) ethanol
was present in the solutions. A Cary Eclipse spectrophotometer
was used to collect emission spectra between 580 and 750 nm
at an excitation of 550 nm.
FT−IR spectroscopy. FT−IR (Bruker-Tensor 37) was
used for the collection of IR spectra of the samples. Only
Fmoc−G−Gem, only Fmoc−AIPs, and Fmoc−G−Gem-
encapsulated Fmoc−AIPs were mixed with potassium bromide
to prepare the pellets by pressing. The IR spectra were
recorded between 4000 and 400 cm−1 at a resolution of 4 cm−1
with 64 scans per sample.
Circular Dichroism. A 0.5% (w/v) solution of Fmoc−AIP1
and Fmoc−AIP2 (5.35 mM) were prepared in water. The pH
adjustment of Fmoc−AIP1 was performed by using NaOH and
kept at pH 8.0, while Fmoc−AIP2 was around pH 6.5 in water.
Solutions were mixed at a 1:1 ratio (200 μL of Fmoc−AIP1 and
200 μL of Fmoc−AIP2) and held at room temperature for 6 h
to achieve co-assembly. Upon mixing with a 1:1 molar ratio, the
pH of Fmoc−AIPs was at around 7.4. Prior to analysis,
solutions were diluted up to 60 μM, and the final Fmoc−G−
Gem concentration within the system was 20 μM. A Jasco J-815
CD spectrophotometer was used for CD analysis, and
measurements were taken between 300 and 190 nm with a
0.1 nm data pitch.
X-ray Powder Diffraction. The β-sheet structure of
Fmoc−AIPs and Fmoc−G−Gem with Fmoc−AIPs was
investigated through a PANanalytical X’Pert powder diffrac-
tometer operating at 45 kV and 40 mA. Samples were ground
and dispersed homogeneously onto the holder, and analyses
were conducted between 2θ = 15°- 30°.
Scanning Transmission Electron Microscopy Imaging.
For STEM imaging of Fmoc−AIPs, Fmoc−G−Gem with
Fmoc−AIPs, and Fmoc−G−Gem, samples were dropped onto
a transmission electron microscopy (TEM) grid, kept for 15
min, washed with water, and stained with 2% (w/v) uranyl
acetate. After drying, a FEI Tecnai G2 F30 STEM instrument
was used for imaging.
Congo Red Staining. Stock Congo red dye (Sigma-
Aldrich) was dissolved in water at a final concentration of 1
mM. For sample preparation, 100 μL of 60 μM Fmoc-AIP1 and
100 μL of 60 μM Fmoc-AIP2 were mixed at pH 7, and 2 μL of
stock Congo red solution was added into mixtures. For the
Fmoc−AIPs with Fmoc−G−Gem system, 1 μL of 4 mM
Fmoc−G−Gem solution was mixed with Fmoc−AIPs at a final
concentration of 20 μM before adding Congo red. The control
group of only Congo red dye was also prepared at a final
concentration of 10 μM. After 2 h of incubation, mixtures were
analyzed through Spectramax M5 microplate reader for
absorbance measurements between 450 and 600 nm.
Controlled Release Behavior. The release of Fmoc−G−
Gem from Fmoc−AIPs was investigated under physiological
conditions (pH 7.4). First, 1% (w/v) Fmoc−AIP1 and Fmoc−
AIP2 were dissolved in water. Initially, 3 μL of Fmoc−G−Gem
(360 mM, dissolved in DMSO) was added to 150 μL of
positively charged Fmoc−AIP2 solution, and then co-assembly
of the system was triggered after the addition of 150 μL of
Fmoc−AIP1 solution. Fmoc−AIPs and Fmoc−AIPs with
Fmoc−G−Gem were formed at the bottom of the quartz
cells and incubated overnight at 37 °C. For Fmoc−AIPs with
Fmoc−G−Gem groups, the final Fmoc−G−Gem concen-
tration was adjusted to 3.6 mM within the system. The release
of Fmoc−G−Gem from Fmoc−AIPs was investigated in PBS
buffer (2700 μL, pH 7.4 at 37 °C). At regular time intervals,
samples were withdrawn and analyzed using a Cary 5000 UV−
vis spectrophotometer between 230 and 400 nm. Only Fmoc−
AIPs, at pH 7.4, were used as a baseline and subtracted from
Fmoc−AIPs with Fmoc−G−Gem to discard the effect of the
peptide. The maximum Fmoc−G−Gem absorbance at 260 nm
was converted into the concentration by calibration curve.
Then, the cumulative release of Fmoc−G−Gem was calculated.
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Cell Culturing and Maintenance. The 4T1 breast cancer
cell line was maintained in Dulbecco’s modified Eagle’s medium
containing 1% antibiotics and 10% fetal bovine serum at 37 °C/
5% CO2.
Dose Determination. In vitro cytotoxicity of Gem-only,
Fmoc−AIPs, Fmoc−G−Gem, and Fmoc−AIPs with Fmoc−
G−Gem treatments was evaluated by Alamar Blue viability test.
Briefly, cells were seeded in 100 μL of culture medium (8 × 103
cells per well) in 96 well plates for 24 and 48 h. The cells were
then exposed to a series of 200 μL samples of Fmoc−G−Gem,
Fmoc−AIPs, Gem-only, or Fmoc−AIPs with Fmoc−G−Gem
solutions of different concentrations in cell culture medium.
After incubation for 24 and 48 h, the medium was discarded,
and 10% (v/v) Alamar blue in cell medium (200 μL) was added
to each well and incubated for 2−3 h. Finally, absorbance was
measured at 570 nm with a Spectramax M5 microplate reader,
and IC50 values were calculated by Graphpad Prism software.
Cell Viability. To determine the effect of Fmoc−G−Gem
on 4T1 apoptosis, a live−dead assay kit (Invitrogen), which
determines esterase activity and plasma membrane integrity,
was used. Briefly, cells were seeded in 100 μL of culture
medium (2.5 × 103 cells per well) in 96 well plates, incubated
for 1 h at 37 °C, and then treated with 200 μL of Gem-only (20
μM), Fmoc−AIPs (60 μM), Fmoc−G−Gem (20 μM), and
Fmoc−AIPs with Fmoc−G−Gem in cell culture medium for
24, 48, 72, and 96 h. Cell viability was determined under an
inverted fluorescence microscope by counting live (green) and
dead (red) cells.
Statistical Analysis. All experiments were independently
repeated at least twice with at least three replicates for each
experimental group. All quantitative results were expressed as ±
standard error of means. Statistical analyses were carried out by
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Figures showing 1H and 13C nuclear magnetic resonance
and mass spectra of Fmoc−G−Gem; liquid chromatog-
raphy−mass spectrometry results of Fmoc−AIPs;
scanning transmission electron microscopy images of
Fmoc−AIPs and Fmoc−AIPs with Fmoc−G−Gem;
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